Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1

Interventions

Specimen Handling 200Magnetic Resonance Spectroscopy 160pembrolizumab 153Carboplatin 117Biopsy 108Cyclophosphamide 100Cisplatin 91Paclitaxel 78Gemcitabine 67Bevacizumab 66Nivolumab 59fludarabine 57Radiotherapy 54Fluorouracil 52Dexamethasone 47Capecitabine 46Oxaliplatin 45Doxorubicin 44Docetaxel 44Pemetrexed 43Rituximab 42Leucovorin 42venetoclax 40durvalumab 38atezolizumab 36Radiation 36Standard of Care 34Prednisone 33Injections 32Cetuximab 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × efineptakin alfa × 30 days × Clear all
NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡